Genomic surveillance as a scalable framework for precision phage therapy against antibiotic-resistant pathogens

Cell. 2024 Oct 17;187(21):5901-5918.e28. doi: 10.1016/j.cell.2024.09.009. Epub 2024 Sep 26.

Abstract

Phage therapy is gaining increasing interest in the fight against critically antibiotic-resistant nosocomial pathogens. However, the narrow host range of bacteriophages hampers the development of broadly effective phage therapeutics and demands precision approaches. Here, we combine large-scale phylogeographic analysis with high-throughput phage typing to guide the development of precision phage cocktails targeting carbapenem-resistant Acinetobacter baumannii, a top-priority pathogen. Our analysis reveals that a few strain types dominate infections in each world region, with their geographical distribution remaining stable within 6 years. As we demonstrate in Eastern Europe, this spatiotemporal distribution enables preemptive preparation of region-specific phage collections that target most local infections. Finally, we showcase the efficacy of phage cocktails against prevalent strain types using in vitro and animal infection models. Ultimately, genomic surveillance identifies patients benefiting from the same phages across geographical scales, thus providing a scalable framework for precision phage therapy.

Keywords: antibiotic resistance; carbapenem-resistant Acinetobacter baumannii; genomic surveillance; nosocomial pathogens; phage cocktail design; phage resistance; phage therapy; phylogeography; region-specific phage collections.

MeSH terms

  • Acinetobacter Infections / microbiology
  • Acinetobacter Infections / therapy
  • Acinetobacter baumannii* / drug effects
  • Acinetobacter baumannii* / genetics
  • Acinetobacter baumannii* / virology
  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacteriophages* / genetics
  • Carbapenems / pharmacology
  • Carbapenems / therapeutic use
  • Drug Resistance, Bacterial / genetics
  • Genomics / methods
  • Humans
  • Mice
  • Phage Therapy* / methods
  • Phylogeography

Substances

  • Anti-Bacterial Agents
  • Carbapenems